Phio Pharmaceuticals Announces New Chief Financial Officer
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company specializing in INTASYL™ siRNA gene silencing technology, has announced the appointment of Robert M. Infarinato as their new Vice President and Chief Financial Officer, effective August 1, 2024. Infarinato brings over 20 years of financial and accounting leadership experience to the role, where he will serve as Principal Financial Officer overseeing accounting, finance, treasury, investor relations, and administration.
Infarinato's extensive background includes leadership positions in healthcare and pharmaceuticals, such as roles at Abington Health, Rhone Poulenc Rorer, and Pfizer. CEO Robert Bitterman expressed enthusiasm about Infarinato joining the executive team, highlighting his broad experience across multiple financial functions within the healthcare sector.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), un'azienda biotecnologica in fase clinica specializzata nella tecnologia di silenziamento genico siRNA INTASYL™, ha annunciato la nomina di Robert M. Infarinato come nuovo Vice Presidente e Chief Financial Officer, a partire dal 1 agosto 2024. Infarinato porta con sé oltre 20 anni di esperienza nella leadership finanziaria e contabile, dove fungerà da Principal Financial Officer supervisionando contabilità, finanza, tesoreria, relazioni con gli investitori e amministrazione.
Il vasto background di Infarinato include posizioni di leadership nel settore sanitario e farmaceutico, come ruoli presso Abington Health, Rhone Poulenc Rorer e Pfizer. Il CEO Robert Bitterman ha espresso entusiasmo per l'ingresso di Infarinato nel team esecutivo, sottolineando la sua ampia esperienza in diverse funzioni finanziarie all'interno del settore sanitario.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), una empresa biotecnológica en etapa clínica especializada en tecnología de silenciamiento génico siRNA INTASYL™, ha anunciado el nombramiento de Robert M. Infarinato como su nuevo Vicepresidente y Director Financiero, efectivo el 1 de agosto de 2024. Infarinato aporta más de 20 años de experiencia en liderazgo financiero y contable al cargo, donde servirá como Principal Financial Officer supervisando contabilidad, finanzas, tesorería, relaciones con inversores y administración.
El amplio trasfondo de Infarinato incluye posiciones de liderazgo en el sector de la salud y farmacéutico, como roles en Abington Health, Rhone Poulenc Rorer y Pfizer. El CEO Robert Bitterman expresó entusiasmo por la incorporación de Infarinato al equipo ejecutivo, destacando su amplia experiencia en múltiples funciones financieras dentro del sector sanitario.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), INTASYL™ siRNA 유전자 침묵 기술에 특화된 임상 단계의 생명공학 회사가 Robert M. Infarinato를 새로운 부사장 겸 최고 재무 책임자로 임명했다고 발표했습니다. 임기는 2024년 8월 1일부터 시작됩니다. Infarinato는 20년 이상의 재무 및 회계 리더십 경력을 이 역할에 가져오며, 회계, 재무, 자산 관리, 투자자 관계 및 관리 업무를 감독하는 Principal Financial Officer로 근무할 것입니다.
Infarinato는 Abington Health, Rhone Poulenc Rorer 및 Pfizer와 같은 의료 및 제약 분야의 리더십 위치를 포함하여 폭넓은 배경을 보유하고 있습니다. CEO Robert Bitterman은 Infarinato가 경영팀에 합류하게 된 것에 대해 열정을 표현하며, 의료 분야 내 다양한 재무 기능에서의 폭넓은 경험을 강조했습니다.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), une entreprise de biotechnologie en phase clinique spécialisée dans la technologie de silencieux génétique siRNA INTASYL™, a annoncé la nomination de Robert M. Infarinato au poste de nouveau Vice-Président et Directeur Financier, effectif à partir du 1er août 2024. Infarinato apporte plus de 20 ans d'expérience en leadership financier et comptable à ce rôle, où il servira en tant que Principal Financial Officer supervisant la comptabilité, les finances, la trésorerie, les relations avec les investisseurs et l'administration.
Le vaste parcours d'Infarinato inclut des postes de direction dans les secteurs de la santé et de la pharmacie, tels que des rôles chez Abington Health, Rhone Poulenc Rorer et Pfizer. Le PDG Robert Bitterman a exprimé son enthousiasme à l'idée de l'arrivée d'Infarinato dans l'équipe exécutive, mettant en avant son expérience variée dans plusieurs fonctions financières au sein du secteur de la santé.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), ein biopharmazeutisches Unternehmen in klinischer Phase, das auf INTASYL™ siRNA-Gentranskriptionstechnologie spezialisiert ist, hat die Ernennung von Robert M. Infarinato zum neuen Vice President und Chief Financial Officer mit Wirkung zum 1. August 2024 bekannt gegeben. Infarinato bringt über 20 Jahre Erfahrung in der finanziellen und buchhalterischen Führung in diese Rolle ein, in der er als Principal Financial Officer die Buchhaltung, Finanzen, Treasury, Investor Relations und Verwaltung überwachen wird.
Infarinatos umfassender Hintergrund umfasst Führungspositionen im Gesundheitswesen und in der Pharmabranche, darunter Rollen bei Abington Health, Rhone Poulenc Rorer und Pfizer. CEO Robert Bitterman äußerte sich begeistert über den Zuwachs von Infarinato im Führungsteam und hob seine umfangreiche Erfahrung in verschiedenen Finanzfunktionen im Gesundheitssektor hervor.
- Appointment of experienced CFO with over 20 years of financial leadership
- New CFO has relevant experience in healthcare and pharmaceutical sectors
- Strengthening of executive team with expertise in finance, accounting, and investor relations
- None.
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the appointment of Robert M. Infarinato to the position of vice president and chief financial officer effective August 1, 2024. He will serve in the capacity of Principal Financial Officer including responsibility for accounting, finance, treasury, investor relations and administration.
Mr. Infarinato comes to Phio with more than 20 years of financial and accounting leadership experience. He most recently was head of a consulting firm, advising on operational matters including the funding and IPO process. Previous positions include serving as Chairman of the Board of Trustees and Chair of the Finance Committee with Abington Health, executive Vice President and CFO of an international service company, Vice President Taxation and Corporate Controller at Rhone Poulenc Rorer, and Treasurer and Tax Manager-Europe for Pfizer.
"I am pleased to welcome Robert to the Phio executive management team," said Robert Bitterman, CEO of Phio Pharmaceuticals. "Bob's skillset is only exceeded by his breadth of experience across multiple financial functions within the health care space. I look forward to his participation as a valuable contributor in guiding our company forward."
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
For additional information, visit the Company's website, www.phiopharma.com.
Contact:
Phio Pharmaceuticals Corp.
ir@phiopharma.com
PR Contact
Michael Adams
Bridge View Media
adams@bridgeviewmedia.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218434
FAQ
Who is the new CFO of Phio Pharmaceuticals (NASDAQ: PHIO)?
What is Robert M. Infarinato's background before joining Phio Pharmaceuticals (NASDAQ: PHIO)?
What are Robert M. Infarinato's responsibilities as CFO at Phio Pharmaceuticals (NASDAQ: PHIO)?
When does Robert M. Infarinato start his role as CFO at Phio Pharmaceuticals (NASDAQ: PHIO)?
